Traditional Chinese medicine plays more and more important roles in treating malignant tumor.Great amount of clinical and basic researches manifested that Chinese medicine can stable tumor Jesion,prolong survival time,improve life quality and so on.As TCM entering an era from sporadic treatments to systemic and standard treatments for malignant tumor,evidence-based medicine leads the basis for it.

Objective To study the clinical effect and influence of Feiliuping Ⅱ on the quality of life quality of lung cancer patients. Methods 60 patients of later stage of lung cancer with definite diagnosis and stages in pathology were chosen, who had approximate condition. Among them, 30 cases were in Chemotherapy-only group, and 30 cases were in Feiliuping Ⅱ +Chemotherapy group. Chemotherapy was the treatment in Chemotherapy-only group. Besides chemotherapy, Feiliuping Ⅱ was taken orally, 20 g tid poin Feiliuping Ⅱ +Chemotherapy group. Three months were a period of treatment. To evaluating effect of two groups from clinical curative effect, symptoms changes, and quality of life. Results After treatment, stable rate of focus were notably higher in Feiliuping Ⅱ +Chemotherapy group than that in Chemotherapy-only group (P

BACKGROUNDIt has been known that there are declines of dendritic cell (DC) count and its function in the peripheral blood of patients with non-small cell lung cancer (NSCLC), which are remarkably related to the proceeding and prognosis of NSCIC. The aim of this study is to investigate the relationship and clinical significance between the DC subsets (CD11c+DC and CD123+DC) and immunology state of patients with advanced NSCLC.

METHODSFlow cytometry was used to detect DC subsets, T cell subsets, NK cell percentage in the peripheral blood of 40 patients with advanced NSCLC and 10 healthy controls.

RESULTSThe expression of CD11c+DC (0.38%±0.18%) in the peripheral blood of advanced NSCLC patients, was decreased significantly compared with that of normal controls (0.66%±0.24%) (P < 0.01). The expression of CD123+DC in the peripheral blood of advanced NSCLC patients was (0.28±0.17)%, with no significant difference compared with that of normal controls (0.27%±0.11%) (P > 0.05). The percentage of CD3+ T cell and CD4+/CD8+ of patients with advanced NSCLC were significantly lower than those of normal controls (P < 0.01 and P < 0.05), and the percentage of CD8+ and NK cell of patients were higher than those of normal controls (P < 0.05). The correlation analysis showed that CD123+DC percentage was positively correlated to CD3+T cell percentage (P < 0.05) and negatively correlated to NK cell percentage (P < 0.01). The expression of DC subsets correlated with KPS and chemotherapy history of patients (P < 0.01).

CONCLUSIONSThe advanced NSCLC may induce significant decreasing expression of CD11c+DC and may induce significant decrease of immunology state. There are close relationship among the expression of DC subsets and the immunology state of patients as well as the clinical biological behaviors of patients with advanced NSCLC.

ObjectiveTo observe the effect of Guben Jiedu prescription （GBJ） on the epithelial-mesenchymal transition （EMT） of lung cancer A549 cells and to explore the mechanism based on phosphoinositide 3-kinase （PI3K）/protein kinase B （Akt） signaling pathway. MethodThe GBJ-medicated serum was prepared. Cell viability was detected by methyl thiazolyl tetrazolium （MTT） assay to screen the optimal doses of GBJ-medicated serum for further experiment. A549 cells were classified into normal serum group， low-， medium-， and high-dose GBJ-medicated serum groups （2.5%， 5%， and 10% GBJ-medicated serum）， PI3K/Akt pathway activator SC79 group， and high-dose GBJ-medicated serum + SC79 group. Cell migration ability was measured by wound-healing assay. The protein expression of E-cadherin， N-cadherin， vimentin， Akt， phosphorylated Akt （p-Akt）， glycogen synthase kinase-3β （GSK-3β）， and phosphorylated GSK-3β （p-GSK-3β） was detected by Western blotting， and the mRNA expression of N-cadherin and vimentin by Real-time PCR. ResultCompared with the normal serum， GBJ-medicated serum （2.5%， 5%， 10%， 20%， 40%） decreased the viability of A549 cells （P<0.05）， and 10%， 5%， 2.5% GBJ-medicated serum was respectively selected for the follow-up experiment. The migration ability of cells in the high-， medium-， and low-dose GBJ-medicated serum groups was lower than that in the normal serum group. The expression of N-cadherin mRNA and Vimentin mRNA in A549 cells in the three GBJ-medicated serum groups was significantly lower than that in the normal serum group （P<0.01）. The protein expression of E-cadherin was higher in the high- and medium-dose GBJ-medicated serum groups than in the normal serum group （P<0.01）. The three GBJ-medicated serum groups showed lower protein expression of N-cadherin， vimentin， p-Akt， and p-GSK-3β （P<0.01） and lower expression of p-Akt/Akt， p-GSK-3β/GSK-3β （P<0.05， P<0.01） than normal serum group. Compared with the SC79 group， the high-dose GBJ-medicated serum group demonstrated high protein expression of E-cadherin （P<0.01） and low expression of N-cadherin， vimentin， p-Akt， p-GSK-3β， and p-Akt/Akt， p-GSK-3β/GSK-3β （P<0.01）. Compared with the high-dose GBJ-medicated serum group， high-dose GBJ-medicated serum + SC79 group showed low protein expression of E-cadherin （P<0.01） and high protein expression of N-cadherin， vimentin， p-Akt， p-GSK-3β， p-Akt/Akt， and p-GSK-3β/GSK-3β （P<0.01）. ConclusionGBJ can inhibit the migration and EMT of lung cancer A549 cells by regulating the PI3K/Akt signaling pathway.